Description

Description

Diajard-L 5/25mg is a prescription medicine manufactured by Highnoon Laboratories, combining two active ingredients, Empagliflozin and Linagliptin, within a single tablet. This fixed-dose combination brings together two distinct mechanisms of blood sugar control, offering a convenient treatment option for adults with type 2 diabetes mellitus whose condition requires more than one approach to management. Empagliflozin belongs to the sodium-glucose co-transporter 2 (SGLT2) inhibitor class, working by reducing glucose reabsorption in the kidneys and promoting its removal through urine. Linagliptin belongs to the dipeptidyl peptidase-4 (DPP-4) inhibitor class, working by helping the body produce more insulin when blood sugar is elevated while also reducing the amount of glucose released by the liver. In this particular strength, the Linagliptin component is present at a higher level compared to some other combinations in the Diajard-L range, while the Empagliflozin dose remains the same, making it typically suited for patients whose treatment plan calls for a greater Linagliptin presence alongside the standard Empagliflozin strength. Each pack of Diajard-L 5/25mg contains 14 tablets, produced under the quality standards maintained by Highnoon Laboratories.

Ingredients

Diajard-L 5/25mg contains two active ingredients: Empagliflozin at a strength of 5 milligrams and Linagliptin at a strength of 25 milligrams per tablet. The formulation also includes standard inactive excipients such as binding agents, fillers, and film-coating materials, which help maintain the tablet’s stability, appearance, and consistent behavior once ingested. These excipients do not contribute to the therapeutic effect but are necessary for proper tablet formulation and stability.

Dosage Form

Diajard-L 5/25mg is available as an oral film-coated tablet. Each pack contains 14 tablets, providing a supply suited to ongoing combination treatment as directed by a prescribing physician. Being an oral solid dosage form, it can be swallowed directly with water without requiring special preparation.

Uses

Diajard-L 5/25mg is used to help improve blood sugar control in adults with type 2 diabetes mellitus, particularly where a physician determines that a higher Linagliptin dose alongside Empagliflozin is appropriate for the patient’s individual needs. It is typically used alongside dietary changes and regular physical activity as part of an overall diabetes management plan. This medicine is not intended for individuals with type 1 diabetes or for the management of diabetic ketoacidosis. The suitability of this combination for any individual patient should always be assessed by a qualified healthcare provider.

How to Use

Diajard-L 5/25mg should be taken exactly as prescribed by a physician, typically once daily in the morning, with or without food. The tablet should be swallowed whole with a glass of water and should not be crushed or chewed. Consistency in timing is generally encouraged to help maintain steady blood sugar control throughout the day. Patients should continue following any dietary or lifestyle guidance given by their doctor and must not adjust the dosage independently. Regular monitoring of blood sugar levels and kidney function is often recommended while using this combination medicine.

Side Effects

Diajard-L 5/25mg may cause side effects in some individuals, though not everyone experiences them. Commonly reported effects include urinary tract infections, genital yeast infections, and increased urination associated with the Empagliflozin component, along with effects linked to the higher Linagliptin strength such as headache, upper respiratory symptoms, or joint discomfort. Some patients may also experience mild dizziness or symptoms related to dehydration. Rare but more serious effects can include signs of pancreatitis, such as persistent abdominal pain, or ketoacidosis with normal blood sugar readings, presenting as nausea, vomiting, or unusual fatigue, both of which require immediate medical attention. Patients with a history of kidney problems, pancreatitis, dehydration, or recurrent urinary infections should discuss these concerns with their doctor before starting treatment, particularly given the higher Linagliptin strength involved.

Pregnancy & Breastfeeding

The use of Diajard-L 5/25mg during pregnancy or breastfeeding should only take place under the specific direction of a qualified healthcare provider, as its suitability in these situations depends on individual clinical circumstances. Women who are pregnant, planning pregnancy, or breastfeeding should discuss their situation with their doctor before starting or continuing this combination medicine.

Storage Instructions

Diajard-L 5/25mg tablets should be stored in a cool, dry place away from direct sunlight and moisture, at the room temperature indicated on the packaging. Tablets should remain in their original blister pack until use to help protect them from humidity and light exposure. Keep out of reach of children and pets, and avoid storing in areas prone to temperature changes, such as bathrooms or vehicles.

FAQS

Q: How is Diajard-L 5/25mg different from the 5/10mg version?
It contains a higher strength of Linagliptin while keeping the same Empagliflozin dose, and is typically prescribed when a greater Linagliptin presence is clinically needed.

Q: Can Diajard-L 5/25mg be taken with food?
Yes, it can be taken with or without food, though maintaining a consistent daily timing is generally encouraged.

Q: Can Diajard-L 5/25mg replace insulin therapy?
No, it works differently from insulin and is not a substitute for insulin therapy in patients who require it.

Q: What should I do if I miss a dose of Diajard-L 5/25mg?
A missed dose should be taken as soon as remembered unless it is close to the next scheduled dose, in which case the missed dose should be skipped rather than doubled, as advised by a doctor.

Disclaimer

Always use this medicine strictly according to your doctor’s instructions and prescribed dosage.